Literature DB >> 24210089

West Nile virus, Texas, USA, 2012.

Kristy O Murray, Duke Ruktanonchai, Dawn Hesalroad, Eric Fonken, Melissa S Nolan.   

Abstract

During the 2012 West Nile virus outbreak in Texas, USA, 1,868 cases were reported. Male patients, persons >65 years of age, and minorities were at highest risk for neuroinvasive disease. Fifty-three percent of counties reported a case; 48% of case-patients resided in 4 counties around Dallas/Fort Worth. The economic cost was >$47.6 million.

Entities:  

Keywords:  Texas; West Nile virus; attack rates; economic impact; epidemiology; outbreak; vector-borne infections; viruses

Mesh:

Year:  2013        PMID: 24210089      PMCID: PMC3837649          DOI: 10.3201/eid1911.130768

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


West Nile virus (WNV) first emerged in Texas, USA, in 2002 (). Since then, the virus has become endemic, with ≈2,200 human cases reported in the state during 2002–2011 (). In 2012, an unprecedented outbreak of WNV occurred in Texas; ≈1,900 cases were reported. The objective of this study was to understand the epidemiology of the 2012 WNV outbreak in Texas.

The Study

WNV infection is a reportable condition in Texas, with clinical cases passively reported by physicians to the local health departments, which in turn report to Texas Department of State Health Services (TxDSHS). We examined surveillance data for all reported cases for which symptom onset occurred during the 2012 calendar year, and we used descriptive statistics to describe the clinical features and demographic characteristics of reported case-patients. We calculated attack rates by sex, age, and race/ethnicity and incidence rates by county using population estimates for 2012 (). Odds ratios (ORs), 95% CIs, and p values were calculated to determine differences in demographic variables between severe disease (WNV neuroinvasive disease [WNND], which included encephalitis, meningoencephalitis, and meningitis) and less severe disease (uncomplicated WNV fever). Epi Info 7.0 software (Centers for Disease Control and Prevention, Atlanta, GA, USA) was used for all statistical calculations. A total of 1,868 cases were reported to TxDSHS during the 2012 transmission season (Table), including 844 (45%) WNND cases and 89 deaths (case-fatality rate 5%). Dates of onset ranged from May 1, 2012, through December 6, 2012 (Figure 1). The outbreak peaked during week 33 (mid-August) with 225 reported cases, which is historically the same peak for all reported WNV cases in Texas during 2002–2011 (). The median time from date of symptom onset to date of official report to TxDSHS was 27 days (range 6–274 days).
Table

Demographic characteristics and attack rates of all West Nile virus cases reported to the Texas (USA) Department of State Health Services during the 2012 outbreak

CharacteristicAll cases, no. (%), n = 1,868Attack rate*/100,000 populationWNV fever, no. (%), n = 1,024WNV neuroinvasive disease, no. (%), n = 844Deaths, no. (%), n = 89
Sex
M1,028 (55.0)8.1519 (50.7)509 (60.3)56 (62.9)
F840 (45.0)6.5505 (49.3)335 (39.7)33 (37.1)
Age, y
<1870 (3.8)1.042 (4.1)28 (3.3)0
18–2471 (3.8)2.742 (4.1)29 (3.4)0
25–44439 (23.5)6.2283 (27.6)156 (18.5)5 (5.6)
45–64728 (39.0)11.7424 (41.4)304 (36.0)13 (14.6)
>65560 (30.0)20.0233 (22.8)327 (38.7)71 (79.8)
Race/ethnicity
White, non-Hispanic1,273 (68.1)11.1738 (72.1)535 (63.4)54 (60.7)
Black117 (6.3)4.043 (4.2)74 (8.8)1 (1.1)
White, Hispanic318 (17.0)3.2134 (13.1)184 (21.8)22 (24.7)
Other/unknown160 (8.6)11.2109 (10.6)51 (6.0)12 (13.5)

*Attack rates based on 2012 population estimates from the Texas State Data Center ().

Figure 1

Number of reported West Nile virus cases, Texas, USA, 2012.

*Attack rates based on 2012 population estimates from the Texas State Data Center (). Number of reported West Nile virus cases, Texas, USA, 2012. When examining the demographic characteristics of the reported cases, we found significant differences in sex, age, and race/ethnicity with regard to severity of disease. Overall, a higher percentage of male case-patients were reported (55%), and male case-patients were significantly more likely than female case-patients to have WNND (OR 1.5, 95% CI 1.2–1.8, p<0.001). Median age of all case-patients was 54 years (range 1 month–100 years). As each age category increased, the attack rates also increased (Table). Persons >65 years of age were significantly more likely than younger persons to have WNND (OR 2.1, 95% CI 1.8–2.6, p<0.001). The median age of the 89 case-patients who died was 79 years (range 25–100 years). When examining race/ethnicity of all cases, we observed the highest attack rate (11.1 cases/100,000 population) in white, non-Hispanics. However, minority populations were significantly more likely to have WNND (OR 1.9, 95% CI 1.6–2.4, p<0.001). Of the 254 counties in Texas, 135 (53%) reported a WNV case (Figure 2). The overall incidence rate for the state was 7.8 cases per 100,000 population. Almost half of the cases were reported from the northeastern quadrant of the state, including the Dallas/Fort Worth metroplex (902 [48%] cases): Dallas (396 [21%]), Tarrant (259 [14%]), Collin (64 [3%]), and Denton (183 [10%]) counties. These 4 counties had a combined incidence rate of 16 cases per 100,000 population.
Figure 2

Incidence rates per 100,000 population during West Nile virus outbreak, Texas, USA, 2012. Numbers in parentheses indicate the number of counties that fell within each range.

Incidence rates per 100,000 population during West Nile virus outbreak, Texas, USA, 2012. Numbers in parentheses indicate the number of counties that fell within each range.

Conclusions

The 2012 WNV outbreak in Texas was unexpected in terms of the magnitude of virus transmission and number of human cases. We recently observed a 3-year pattern of increases in reported human cases in Texas, as seen in 2003, 2006, and 2009 (). In 2012, the dramatic epidemic was consistent with this prior observation, with the 1,868 reported cases being more than double the historic high, which occurred in 2003 (735 cases). In addition to the dramatic increase in human cases in 2012, the state also reported an increase in equine cases (121 cases in 2012 compared with 6 cases in 2011). The exact factors that contributed to this epidemic are unknown and most likely complex, considering that successful transmission depends on supportive environmental conditions, vector abundance, avian reservoir and susceptible host abundance, pathogenicity of the virus, and sizeable populations of immunologically naive reservoir species. WNV more severely affects persons >65 years of age; deaths typically are reported in elderly presons (,). During 2012, there was some media speculation that more cases of severe disease occurred in younger persons and that the circulating strain of virus possibly was more pathogenic than in prior years. Compared with Texas data for 2002–2011, we did not find any statistically significant differences in median ages of reported WNND or fatal cases in 2012 using the Kruskal-Wallis 1-way analysis of variance on ranks. Our findings from 2012 remain consistent with our experience from prior years; however, it remains critical to emphasize the importance of recognizing disease and testing persons of any age who have clinical signs and symptoms consistent with WNV infection. The 2012 WNV outbreak in Texas greatly affected the state economically. On the basis of the acute medical care and productivity loss cost estimates provided by Barber et al. () (adjusted to 2012 USD), we crudely estimate the 2012 outbreak in Texas cost ≈$47.6 million (range $14.5–$140.7 million; Technical Appendix Table). In addition to these acute costs, the outbreak also required an increase in resources for mosquito control and public health efforts to respond to the epidemic. A recent study reported the cost of aerial spraying alone in Dallas County exceeded $1.6 million (). The long-term economic impact of this outbreak also is expected to be substantial as a consequence of long-term rehabilitation and disability costs (), possible risk for chronic kidney disease (), and risk for premature death in severe cases (). The unprecedented 2012 outbreak confirms the need for continued vigilance for surveillance to enable timely implementation of control measures to prevent virus transmission. We expect Texas will continue to experience endemic levels of virus transmission with periodic epizootics. Considering the economic and physical costs to persons severely affected, development of an effective vaccine is urgently needed to prevent disease. Until a vaccine becomes available, public health authorities will need to maintain their focus on surveillance, disease recognition, implementation of control measures, and public education about protective measures.

Technical Appendix

Calculations for economic costs of West Nile virus, Texas, USA, 2012.
  9 in total

1.  The 2002 introduction of West Nile virus into Harris County, Texas, an area historically endemic for St. Louis encephalitis.

Authors:  Kristy M Lillibridge; Ray Parsons; Yvonne Randle; Amelia P A Travassos da Rosa; Hilda Guzman; Marina Siirin; Taweesak Wuithiranyagool; Christina Hailey; Stephen Higgs; Adil A Bala; Rhia Pascua; Tamra Meyer; Dana L Vanlandingham; Robert B Tesh
Journal:  Am J Trop Med Hyg       Date:  2004-06       Impact factor: 2.345

2.  The outbreak of West Nile virus infection in the New York City area in 1999.

Authors:  D Nash; F Mostashari; A Fine; J Miller; D O'Leary; K Murray; A Huang; A Rosenberg; A Greenberg; M Sherman; S Wong; M Layton
Journal:  N Engl J Med       Date:  2001-06-14       Impact factor: 91.245

3.  Risk factors for encephalitis and death from West Nile virus infection.

Authors:  K Murray; S Baraniuk; M Resnick; R Arafat; C Kilborn; K Cain; R Shallenberger; T L York; D Martinez; J S Hellums; D Hellums; M Malkoff; N Elgawley; W McNeely; S A Khuwaja; R B Tesh
Journal:  Epidemiol Infect       Date:  2006-05-04       Impact factor: 2.451

4.  Delayed mortality in a cohort of persons hospitalized with West Nile virus disease in Colorado in 2003.

Authors:  Nicole P Lindsey; James J Sejvar; Amy V Bode; W John Pape; Grant L Campbell
Journal:  Vector Borne Zoonotic Dis       Date:  2011-10-24       Impact factor: 2.133

5.  The 2012 West Nile encephalitis epidemic in Dallas, Texas.

Authors:  Wendy M Chung; Christen M Buseman; Sibeso N Joyner; Sonya M Hughes; Thomas B Fomby; James P Luby; Robert W Haley
Journal:  JAMA       Date:  2013-07-17       Impact factor: 56.272

6.  Neurologic manifestations and outcome of West Nile virus infection.

Authors:  James J Sejvar; Maryam B Haddad; Bruce C Tierney; Grant L Campbell; Anthony A Marfin; Jay A Van Gerpen; Aaron Fleischauer; A Arturo Leis; Dobrivoje S Stokic; Lyle R Petersen
Journal:  JAMA       Date:  2003-07-23       Impact factor: 56.272

7.  Economic cost analysis of West Nile virus outbreak, Sacramento County, California, USA, 2005.

Authors:  Loren M Barber; Jerome J Schleier; Robert K D Peterson
Journal:  Emerg Infect Dis       Date:  2010-03       Impact factor: 6.883

8.  Prevalence of chronic kidney disease and progression of disease over time among patients enrolled in the Houston West Nile virus cohort.

Authors:  Melissa S Nolan; Amber S Podoll; Anne M Hause; Katherine M Akers; Kevin W Finkel; Kristy O Murray
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

9.  West Nile virus infection among humans, Texas, USA, 2002-2011.

Authors:  Melissa S Nolan; Jim Schuermann; Kristy O Murray
Journal:  Emerg Infect Dis       Date:  2013-01       Impact factor: 6.883

  9 in total
  26 in total

Review 1.  Current trends in West Nile virus vaccine development.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Expert Rev Vaccines       Date:  2014-04-01       Impact factor: 5.217

2.  An outbreak of West Nile Virus infection in the region of Monastir, Tunisia, 2003.

Authors:  Samira Riabi; Imed Gaaloul; Maha Mastouri; Mohsen Hassine; Mahjoub Aouni
Journal:  Pathog Glob Health       Date:  2014-04       Impact factor: 2.894

Review 3.  Risk factors for West Nile virus infection and disease in populations and individuals.

Authors:  Ruth R Montgomery; Kristy O Murray
Journal:  Expert Rev Anti Infect Ther       Date:  2015-01-30       Impact factor: 5.091

Review 4.  New insights into innate immune restriction of West Nile virus infection.

Authors:  Helen M Lazear; Michael S Diamond
Journal:  Curr Opin Virol       Date:  2014-12-31       Impact factor: 7.090

5.  Role of the Vector in Arbovirus Transmission.

Authors:  Michael J Conway; Tonya M Colpitts; Erol Fikrig
Journal:  Annu Rev Virol       Date:  2014-06-02       Impact factor: 10.431

Review 6.  A 20-year historical review of West Nile virus since its initial emergence in North America: Has West Nile virus become a neglected tropical disease?

Authors:  Shannon E Ronca; Jeanne C Ruff; Kristy O Murray
Journal:  PLoS Negl Trop Dis       Date:  2021-05-06

7.  Enhancing pathogen identification in patients with meningitis and a negative Gram stain using the BioFire FilmArray(®) Meningitis/Encephalitis panel.

Authors:  Susan H Wootton; Elizabeth Aguilera; Lucrecia Salazar; Andrew C Hemmert; Rodrigo Hasbun
Journal:  Ann Clin Microbiol Antimicrob       Date:  2016-04-21       Impact factor: 3.944

Review 8.  Apoptosis, autophagy and unfolded protein response pathways in Arbovirus replication and pathogenesis.

Authors:  Mahmoud Iranpour; Adel Rezaei Moghadam; Mina Yazdi; Sudharsana R Ande; Javad Alizadeh; Emilia Wiechec; Robbin Lindsay; Michael Drebot; Kevin M Coombs; Saeid Ghavami
Journal:  Expert Rev Mol Med       Date:  2016-01-19       Impact factor: 5.600

Review 9.  Mechanisms of innate immune evasion in re-emerging RNA viruses.

Authors:  Daphne Y Ma; Mehul S Suthar
Journal:  Curr Opin Virol       Date:  2015-03-09       Impact factor: 7.090

10.  Survival analysis, long-term outcomes, and percentage of recovery up to 8 years post-infection among the Houston West Nile virus cohort.

Authors:  Kristy O Murray; Melissa N Garcia; Mohammad H Rahbar; Diana Martinez; Salma A Khuwaja; Raouf R Arafat; Susan Rossmann
Journal:  PLoS One       Date:  2014-07-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.